Tumor Mutational Burden and Response Rate to PD-1 Inhibition

To the Editor: Inhibitors of programmed death 1 (PD-1) protein or its ligand (PD-L1) have shown remarkable clinical benefit in many cancers. One emerging biomarker of response to anti–PD-1 therapy is the tumor mutational burden (i.e. the total number of mutations per coding area of a tumor genome).…

http://ift.tt/2p16iVX